insightsZ as # 1 Alternative Data Provider
Over the past 24 months, insightsZ has positioned itself as a leading provider of alternative data. Our clientele includes some of the largest asset management and investment firms globally, collectively managing assets exceeding USD 100 billion as AUM. Additionally, the combined market cap of our industrial clients also exceeds USD 100 billion.
We would like to express our sincere appreciation to our clients for their continued trust in our research & analytics.
Our capabilities enable more accurate predictions of brand performance, facilitate technology forecasting, and provide insights beyond just traditional marketing and financial metrics. Our analytics empower manufacturers and DSOs to refine their innovation and commercial strategies, as well as foster more data-driven decision-making. While insightsZ alternative data is not intended to replace traditional data sources, it is designed to complement them, offering a more comprehensive, 360-degree perspective that enhances both strategic planning and informed decision-making.
Recent Cyberattack Incident
On January 13, 2025, at 18:17 CET/09:17 PST, we observed suspicious activity on our website. This was not an isolated incident, but part of a series of recent targeted attacks. We have successfully traced the geographical locations from which the attack originated, and where it was sponsored. The recent breach resulted in unrealized revenue losses and technical disruptions for insightsZ website.
However, we would like to clarify that:
No customer data or payment information was compromised during the attack.
The primary objective of the attack was to exploit vulnerabilities on our website, to access and download proprietary research content.
Rather than downplay this cyberattack, we have chosen to speak about the incident. However, please acknowledge that we will not be disclosing further specifics at this time, as they are crucial to upcoming discussions with investigative and legal authorities.
We consider this attack to be a serious matter, not only due to the severity of the incident, but also because it demonstrates the lengths to which large organizations may go to retaliate against whistleblowers, despite their public commitment to ethics and compliance. This is particularly concerning when they are faced with information and free speech that challenge their interests, even if it means placing their own agendas above patient health and the rights of investors.
The Whistleblowing Incident
October 2024, insightsZ published an article discussing the potential market exit of a leading DTC clear aligner brand, highlighting the unprecedented spike in Adverse Events Reports and Patient Injuries that kept pouring-in during FY2023 and FY2024.
insightsZ clarified that the manufacturer’s decision to exit the market was not solely driven by the evolving state regulatory environment (which based on the company’s PR has had adversely impacted the manufacturer’s DTC business model --> resulting in declining conversion rates and revenues).
insightsZ made a deep dive into the FDA’s MAUDE database, which houses medical device reports (MDRs) submitted to the FDA by mandatory reporters (manufacturers, importers and device user facilities) and voluntary reporters such as health care professionals, patients and consumers.
We would like to make it clear that insightsZ didn’t cross any lines concerning how the data was reported, analysed or even processed. Our research was aimed at demonstrating that there is a significant correlation between the suspension of the company’s DTC clear aligner business AND the recent sudden unprecedented spike in Adverse Events Reports and Patient Injuries that were submitted during FY2023 and FY2024 (Note: More than 900 event reports were submitted in the months of OCT’24 alone).
Outcome – As a result, multiple law firms have filed a series of class-action lawsuits against the manufacturer, accusing it of securities law violations, including misleading investors and materially overstating the goodwill value of its DTC business unit. The lawsuits allege that the manufacturer made false and misleading statements during the Class Period (from May 6, 2021, to November 6, 2024), and failed to disclose material adverse facts about its business, operations, and future prospects.
Additionally, the manufacturer is accused of being aware of severe patient injuries caused by its DTC clear aligners, but failing to adequately investigate the incidents or report them to the FDA, thereby violating post-marketing surveillance and CAPA (Corrective and Preventive Action) guidelines.
At insightsZ, we emphasize the critical importance of addressing retaliatory actions against whistleblowers, especially when it pertains to protecting patient health, preserving the integrity of the dental manufacturing and services industry, and promoting ethical corporate conduct. We would like to affirm that no retaliatory measures will dissuade us from reporting our findings. We remain steadfast in our commitment to identifying and addressing violations of investors' rights, including corporate mismanagement and breaches of fiduciary duty by executives, among other concerns.
Disclaimer:
The content of this website is NOT an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. Although the content in the website articles has been taken from sources that are believed to be accurate, no warranty or representation is made by insightsZ as to its correctness, completeness, timeliness or accuracy. insightsZ does not assume or undertake any duty to advise any person or investor, and accept no liability whatsoever for any direct, indirect or consequential loss arising from or in connection with any use or reliance of this Information or anything contained in it. insightsZ is not a registered investment, tax or legal advisor or a broker/dealer.